Prevention of SARS-CoV-2 infection. To evaluate the benefit of imatinib mesylate to prevent the SRAS-Cov 2 contamination in nursing home residents. Prevention of severe COVID-19 disease. To evaluate the benefit of early imatinib to prevent severe COVID-19 disease in hospitalized aged patients.

Prevention of SARS-CoV-2 infection. To evaluate the benefit of imatinib mesylate to prevent the SRAS-Cov 2 contamination in nursing home residents. Prevention of severe COVID-19 disease. To evaluate the benefit of early imatinib to prevent severe COVID-19 disease in hospitalized aged patients.